SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Manuel Comabella, Xavier Montalban, Body fluid biomarkers in multiple sclerosis, The Lancet Neurology, 2014, 13, 1, 113

    CrossRef

  2. 2
    Consider switching to another disease-modifying therapy when unacceptable disease activity occurs in relapsing multiple sclerosis, Drugs & Therapy Perspectives, 2014, 30, 4, 141

    CrossRef

  3. 3
    Renaud A. Du Pasquier, Daniel D. Pinschewer, Doron Merkler, Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis, CNS Drugs, 2014,

    CrossRef

  4. 4
    Bernd C Kieseier, The challenges of measuring disability accumulation in relapsing–remitting multiple sclerosis: evidence from interferon beta treatments, Expert Review of Neurotherapeutics, 2014, 14, 1, 105

    CrossRef

  5. 5
    Paul M Matthews, Olivia C Geraghty, Understanding the pharmacology of stroke and multiple sclerosis through imaging, Current Opinion in Pharmacology, 2014, 14, 34

    CrossRef

  6. 6
    Jack H. Simon, Multiple Sclerosis and Related Disorders, 2014,

    CrossRef

  7. 7
    Maria Pia Sormani, Nicola De Stefano, Defining and scoring response to IFN-β in multiple sclerosis, Nature Reviews Neurology, 2013, 9, 9, 504

    CrossRef

  8. 8
    Frühe Prädiktoren für den Langzeitverlauf unter Interferon-beta-1a-Therapie, InFo Neurologie & Psychiatrie, 2013, 15, 5, 24

    CrossRef

  9. 9
    G. Edan, L’IRM est-elle utile dans le suivi des patients atteints de sclérose en plaques ? Non, Revue Neurologique, 2013, 169, 11, 864

    CrossRef

  10. 10
    B. Brochet, L’IRM est-elle utile dans le suivi des patients atteints de sclérose en plaques ? Oui, Revue Neurologique, 2013, 169, 11, 858

    CrossRef

  11. 11
    Robert A. Bermel, Laura J. Balcer, Optic Neuritis and the Evaluation of Visual Impairment in Multiple Sclerosis, CONTINUUM: Lifelong Learning in Neurology, 2013, 19, 1074

    CrossRef

  12. 12
    Patricia K. Coyle, Switching Therapies in Multiple Sclerosis, CNS Drugs, 2013, 27, 4, 239

    CrossRef

  13. 13
    Paul M. Matthews, Paul Edison, Olivia C. Geraghty, Michael R. Johnson, The emerging agenda of stratified medicine in neurology, Nature Reviews Neurology, 2013, 10, 1, 15

    CrossRef

  14. 14
    Thomas R. Insel, Story C. Landis, Twenty-Five Years of Progress: The View from NIMH and NINDS, Neuron, 2013, 80, 3, 561

    CrossRef